Home > In process > Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter study. > print

001     285032
005     20260206165952.0
024 7 _ |a 10.1080/21678421.2025.2557932
|2 doi
024 7 _ |a pmid:40932199
|2 pmid
024 7 _ |a 2167-8421
|2 ISSN
024 7 _ |a 2167-9223
|2 ISSN
037 _ _ |a DZNE-2026-00157
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Spittel, Susanne
|0 0000-0001-9471-7798
|b 0
245 _ _ |a Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter study.
260 _ _ |a Abingdon
|c 2026
|b Taylor Francis Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770393387_713
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a In amyotrophic lateral sclerosis (ALS), dextromethorphan/quinidine (DMQ) has been reported to reduce bulbar symptoms, including dysarthria and dysphagia. However, data on patients' perceptions of DMQ treatment are limited.Data on DMQ treatment were collected from 1065 ALS patients treated at 13 ALS centers between 10-2015 and 06-2025. Patient-reported outcome measures (PROM) of 179 participants were remotely assessed via the 'ALS App'. PROM included the self-explanatory version of the ALS Functional Rating Scale (ALSFRS-R-SE), the Net Promoter Score (NPS); and Treatment Satisfaction Questionnaire for Medication (TSQM-9).Mean disease duration was 29.3 months (SD 38.1). ALS progression before treatment was 0.82 points/month (ALSFRS-R). Mean DMQ treatment duration was 8.4 months (SD 10.8), including 35.2% (n = 374) of shorter (<3 months), 35.3% (n = 375) of longer (3-9 months), and 29.5% (n = 313) of very long DMQ treatment (>9 months). Patients' recommendation (n = 178) was positive (NPS: +23) with higher scores after very long DMQ treatment (NPS +37) compared to longer (NPS +15) and shorter treatment (NPS +7.5), respectively. TSQM-9 scores (n = 163) demonstrated high satisfaction for effectiveness 60.0 (SD 25.9), convenience 73.8 (SD 18.2), and global satisfaction 63.4 (SD 29.8).The positive perception in PROM underscores the value of DMQ as an individualized treatment option for bulbar symptoms in ALS. However, shortage of clinical data, online assessment, and selection biases are among the limitations of this study that need to be addressed in further investigations.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Amyotrophic lateral sclerosis
|2 Other
650 _ 7 |a bulbar symptoms
|2 Other
650 _ 7 |a dextromethorphan/quinidine (DMQ)
|2 Other
650 _ 7 |a dysarthria
|2 Other
650 _ 7 |a dysphagia
|2 Other
650 _ 7 |a patient-reported outcomes
|2 Other
650 _ 7 |a Dextromethorphan
|0 7355X3ROTS
|2 NLM Chemicals
650 _ 7 |a Quinidine
|0 ITX08688JL
|2 NLM Chemicals
650 _ 7 |a dextromethorphan - quinidine combination
|2 NLM Chemicals
650 _ 7 |a Drug Combinations
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Dextromethorphan: therapeutic use
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: drug therapy
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: complications
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Quinidine: therapeutic use
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Patient Reported Outcome Measures
|2 MeSH
650 _ 2 |a Drug Combinations
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Patient Satisfaction
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
700 1 _ |a Grehl, Torsten
|b 1
700 1 _ |a Weydt, Patrick
|0 P:(DE-2719)9001116
|b 2
|u dzne
700 1 _ |a Kettemann, Dagmar
|b 3
700 1 _ |a Fabian, Rachel
|b 4
700 1 _ |a Rödiger, Annekathrin
|b 5
700 1 _ |a Smesny, Uta
|b 6
700 1 _ |a Steinbach, Robert
|b 7
700 1 _ |a Ilse, Benjamin
|b 8
700 1 _ |a Weyen, Ute
|b 9
700 1 _ |a Petri, Susanne
|b 10
700 1 _ |a Lumi, Rea
|b 11
700 1 _ |a Bjelica, Bogdan
|b 12
700 1 _ |a Lingor, Paul
|0 P:(DE-2719)2812561
|b 13
|u dzne
700 1 _ |a Grosskreutz, Julian
|b 14
700 1 _ |a Göricke, Bettina M
|b 15
700 1 _ |a Pfeilschifter, Waltraud
|b 16
700 1 _ |a Schmeja, Wibke
|b 17
700 1 _ |a Dorst, Johannes
|0 P:(DE-2719)9001951
|b 18
|u dzne
700 1 _ |a Mensch, Alexander
|b 19
700 1 _ |a Siebert, Jürgen
|b 20
700 1 _ |a Norden, Jenny
|b 21
700 1 _ |a Bernsen, Sarah
|0 P:(DE-2719)9000485
|b 22
|u dzne
700 1 _ |a Subramanian, Senthil Kumar
|0 0000-0001-6853-9895
|b 23
700 1 _ |a Hildebrandt, Barbara
|b 24
700 1 _ |a Walter, Bertram
|b 25
700 1 _ |a Münch, Christoph
|b 26
700 1 _ |a Maier, André
|0 0000-0003-2473-4116
|b 27
700 1 _ |a Meyer, Thomas
|0 0000-0002-2736-7350
|b 28
773 _ _ |a 10.1080/21678421.2025.2557932
|g Vol. 27, no. 1-2, p. 185 - 197
|0 PERI:(DE-600)2705061-0
|n 1-2
|p 185 - 197
|t Amyotrophic lateral sclerosis & frontotemporal degeneration
|v 27
|y 2026
|x 2167-8421
856 4 _ |u https://pub.dzne.de/record/285032/files/DZNE-2026-00157.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285032/files/DZNE-2026-00157.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9001116
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 13
|6 P:(DE-2719)2812561
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)9001951
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)9000485
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AMYOTROPH LAT SCL FR : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-01
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-01
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 0
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 1
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)5000077
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21